SCHEMBL503819

SCHEMBL503819

O=C(O)CC(CC(=O)O)c1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABBR2 O75899 4/20 0.76
▸ GABBR1 Q9UBS5 4/20 0.76
▸ MAPT P10636 1/20 0.65
▸ MEN1 O00255 2/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ RECQL P46063 1/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ APEX1 P27695 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ LMNA P02545 2/20 0.52
▸ CYP2C9 P11712 2/20 0.52
▸ CYP2C19 P33261 2/20 0.52
▸ CYP1A2 P05177 2/20 0.52
▸ CYP2D6 P10635 2/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ ADORA3 P0DMS8 1/20 0.52
▸ NFKB1 P19838 1/20 0.52
▸ DRD3 P35462 1/20 0.52
▸ BLM P54132 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6734410 0.98 GABBR2 (0.73) GABBR2GABBR1MAPTMEN1KMT2A
Hydrochloric Acid SCHEMBL7092228 0.98 GABBR2 (0.73) GABBR2GABBR1MAPTMEN1KMT2A
Alcohol SCHEMBL28575312 0.91 GABBR2 (0.66) GABBR2GABBR1MAPTMEN1KMT2A
SCHEMBL16249736 0.90 GABBR2 (0.61) GABBR2GABBR1MAPTMEN1KMT2A
SCHEMBL9857550 0.89 GABBR2 (0.63) GABBR2GABBR1MAPTMEN1KMT2A
SCHEMBL27814502 0.89 GABBR2 (0.69) GABBR2GABBR1MAPTMEN1KMT2A
SCHEMBL3728800 0.89 GABBR2 (0.68) GABBR2GABBR1MAPTMEN1KMT2A
SCHEMBL657290 0.88 GABBR2 (0.61) GABBR2GABBR1MAPTMEN1KMT2A
SCHEMBL9541616 0.88 GABBR2 (0.61) GABBR2GABBR1MAPTMEN1KMT2A
SCHEMBL16616451 0.88 ATM (0.68) GABBR2GABBR1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 681 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120114428-A Application of 3-phenyl glutaric acid derivative 84-B10 in preparing myocardial protection medicine 南京市儿童医院 2025-06-10 — — CN claimed
CN-120000626-A Pharmaceutical use and pharmaceutical composition of 3-phenyl glutaric acid derivative 安徽医科大学第一附属医院 2025-05-16 — — CN claimed
CN-119798627-A Method for preparing hydroxyl-terminated high molecular polyester polyol without metal catalyst and polyester polyol 北京高盟新材料股份有限公司 2025-04-11 — — CN claimed
CN-118852022-B Gemini quaternary ammonium salt antibacterial agent, preparation thereof and application thereof in antibacterial polyester synthesis 浙江大学 2025-03-28 — — CN claimed
WO-2025021165-A1 POLYMER COMPRISING ESTER-IMIDE STRUCTURAL UNIT, AND PREPARATION METHOD THEREFOR 西湖大学 2025-01-30 — — WO claimed
CN-118852022-A Gemini quaternary ammonium salt antibacterial agent, preparation thereof and application thereof in antibacterial polyester synthesis 浙江大学 2024-10-29 — — CN claimed
CN-115813901-B Application of 3-phenyl glutaric acid derivative small molecule in preparation of medicament for preventing and treating cisplatin-induced acute kidney injury 南京市儿童医院 2024-10-22 — — CN claimed
CN-116444751-B All-water spraying winding polyol composite material, polyurethane rigid foam plastic and preparation method of polyurethane rigid foam plastic heat-insulation pipeline 万华化学(宁波)容威聚氨酯有限公司 2024-06-25 — — CN claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 — — CN claimed
US-11912818-B2 Method for synthesizing aromatic-aliphatic copolyester without catalyst and product thereof ZHEJIANG UNIVERSITY (CN) 2024-02-27 — — US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 — — US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 — — US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 — — US claimed
US-6989052-B1 Phase change ink printing process XEROX CORPORATION (US) 2006-01-24 — — US claimed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 — — US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 — — US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 — — US claimed
US-5683793-A Ink jet transparencies XEROX CORPORATION (US) 1997-11-04 — — US claimed
US-5589277-A INK JET PRINTING, AQUEOUS INKS, FAST DRYING XEROX CORPORATION (US) 1996-12-31 — — US claimed
EP-0667246-A1 Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds XEROX CORPORATION (US) 1995-08-16 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 GABBR2 2796/4885GABBR1 3403/4885MAPT 4074/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 GABBR2 4009/4885GABBR1 4132/4885MAPT 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback